JP2006513185A - Ｎ−ピラゾリル−ｎ’−ナフチル−尿素の実質的に純粋な多形体の調製方法 - Google Patents

Ｎ−ピラゾリル−ｎ’−ナフチル−尿素の実質的に純粋な多形体の調製方法 Download PDF

Info

Publication number
JP2006513185A
JP2006513185A JP2004561284A JP2004561284A JP2006513185A JP 2006513185 A JP2006513185 A JP 2006513185A JP 2004561284 A JP2004561284 A JP 2004561284A JP 2004561284 A JP2004561284 A JP 2004561284A JP 2006513185 A JP2006513185 A JP 2006513185A
Authority
JP
Japan
Prior art keywords
ethanol
polymorph
crude
substantially pure
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004561284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513185A5 (enExample
Inventor
ヴェンデリン ザムシュターク
ギュンター コッホ
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2006513185A publication Critical patent/JP2006513185A/ja
Publication of JP2006513185A5 publication Critical patent/JP2006513185A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004561284A 2002-12-23 2003-12-12 Ｎ−ピラゾリル−ｎ’−ナフチル−尿素の実質的に純粋な多形体の調製方法 Pending JP2006513185A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43613602P 2002-12-23 2002-12-23
PCT/EP2003/014128 WO2004056783A1 (en) 2002-12-23 2003-12-12 Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea

Publications (2)

Publication Number Publication Date
JP2006513185A true JP2006513185A (ja) 2006-04-20
JP2006513185A5 JP2006513185A5 (enExample) 2007-02-08

Family

ID=32682346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004561284A Pending JP2006513185A (ja) 2002-12-23 2003-12-12 Ｎ−ピラゾリル−ｎ’−ナフチル−尿素の実質的に純粋な多形体の調製方法

Country Status (6)

Country Link
US (1) US20040138216A1 (enExample)
EP (1) EP1581502A1 (enExample)
JP (1) JP2006513185A (enExample)
AU (1) AU2003298178A1 (enExample)
CA (1) CA2511325A1 (enExample)
WO (1) WO2004056783A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1716121A1 (en) * 2003-12-18 2006-11-02 Boehringer Ingelheim Pharmaceuticals Inc. Polymorph of birb 796, a p38map kinase inhibitor
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
JP2010524970A (ja) 2007-04-20 2010-07-22 デシフェラ ファーマシューティカルズ，エルエルシー 骨髄増殖性疾患及びその他の増殖性疾患の治療に有用なキナーゼ阻害剤
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043384A1 (en) * 1999-01-19 2000-07-27 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
WO2001004115A2 (en) * 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263336B2 (ja) * 2000-04-12 2009-05-13 パイオニア株式会社 プラズマディスプレイパネルの隔壁構造
EP1362037A1 (en) * 2001-02-15 2003-11-19 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043384A1 (en) * 1999-01-19 2000-07-27 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
WO2001004115A2 (en) * 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds

Also Published As

Publication number Publication date
EP1581502A1 (en) 2005-10-05
AU2003298178A1 (en) 2004-07-14
WO2004056783A1 (en) 2004-07-08
CA2511325A1 (en) 2004-07-08
US20040138216A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
CN109422752B (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
KR101811997B1 (ko) １­클로로­４­（베타­ｄ­글루코피라노스­１­일）­２­（４­（（ｓ）­테트라하이드로푸란­３­일옥시）벤질）벤젠의 결정형의 제조방법
EP2611779B1 (en) CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
EP1506196A2 (en) Pyrazolopyrimidines
EP1451160A2 (en) Pyrazole-amides and-sulfonamides
JP2006513185A (ja) Ｎ−ピラゾリル−ｎ’−ナフチル−尿素の実質的に純粋な多形体の調製方法
EA026102B1 (ru) МОДУЛЯТОРЫ СВЯЗАННОГО С РЕТИНОИДОМ СИРОТСКОГО РЕЦЕПТОРА ГАММА (RORγ)
WO2003037890A2 (en) Piperidines
EP3974422A1 (en) Compound used as ret kinase inhibitor and application thereof
CN103459381A (zh) 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
CN118978514A (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
JPH06500085A (ja) ベンズイミダゾール、その製造および使用法
WO2008061456A1 (en) The folacin-metformin compound and its manufacture
JP5972986B2 (ja) Ｃｄｄｏエチルエステルの多形体及びその用途
EA005856B1 (ru) Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
JP2014534208A5 (enExample)
CN103319402A (zh) 二苯基硫脲类衍生物及其制备方法和应用
CN108947952A (zh) 2-取代氨基-5-三氟甲基-8-硝基苯并（硫代）吡喃-4-酮类化合物及其制备方法和用途
WO2017008684A1 (zh) 化合物A的晶型α及其制备方法和含有该晶型的药物组合物
KR102544543B1 (ko) L,d-엘도스테인의 개별적 공결정화물
EP4516781A1 (en) Compound for reducing uric acid
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
CN1110489C (zh) 苯并异硒唑酮磺酰胺衍生物及其制法和其在制备药物中的应用
JP2022542518A (ja) 終末糖化産物の抑制剤
CN115710253A (zh) 一类含有氨基苯并咪唑类衍生物及其制备和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101122